An antimicrobial modified silicone peritoneal catheter with activity against both Gram positive and Gram negative bacteria

Biomaterials

Volumn 30, Issue 18, 2009, Pages 3167-3173

  Bayston, Roger ^a   Fisher, Leanne E ^a   Weber, Klaus ^b  

^a Institute of Neuroscience   (United Kingdom)

^b RCC Ltd   (Switzerland)

Author keywords

Antimicrobial catheter; Continuous ambulatory peritoneal dialysis (CAPD); Rifampicin; Triclosan; Trimethoprim

Indexed keywords

ANTIMICROBIAL CATHETER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD); RIFAMPICIN; TRICLOSAN; TRIMETHOPRIM;

BACTERIOLOGY; DIALYSIS; ESCHERICHIA COLI; SILICONES; SULFUR COMPOUNDS;

CATHETERS;

R 3501; RIFAMPICIN; SILICONE; T 7883; TRICLOSAN; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; ESCHERICHIA COLI; EXPERIMENTAL MODEL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MATERIAL COATING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; PERITONEAL CATHETER; PRIORITY JOURNAL; TREATMENT DURATION;

ANIMALS; CATHETER-RELATED INFECTIONS; CATHETERS, INDWELLING; COATED MATERIALS, BIOCOMPATIBLE; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MALE; MATERIALS TESTING; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED STRAINS; MICROBIAL SENSITIVITY TESTS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RIFAMPIN; SILICONES; STAPHYLOCOCCUS EPIDERMIDIS; TRICLOSAN; TRIMETHOPRIM;

ESCHERICHIA COLI; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 64849088287     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.02.028     Document Type: Article

References (33)

1. Thodis E., Passadakis P., Lyrantzopooulos N., Panagoutsos S., Vargemezis V., and Oreopoulos D. Peritoneal catheters and related infections. Int Urol Nephrol 37 (2005) 379-393
2. Chitalia V.C., Almeida A.F., Rai H., Bapat M., Chitalia K.V., Acharya V.N., et al. Is peritoneal dialysis adequate for hypercatabolic acute renal failure in developing countries?. Kidney Int 61 (2002) 747-757
3. Vikrant S. Continuous ambulatory peritoneal dialysis: a viable modality of renal replacement therapy in a hilly state of India. Indian J Nephrol 17 4 (2007) 165-169
4. Thodis E., Bhaskaran S., Pasadakis P., Bargman J.M., Vas S.I., and Oreopoulos D.G. Decrease in Staphylococcus aureus exit site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter site. Perit Dial Int 18 3 (1998) 261-270
5. Gorman S.P., Adair C.G., and Mawhinney W.M. Incidence and nature of peritoneal catheter biofilm determined by electron and confocal laser scanning microscopy. Epidemiol Infect 112 3 (1994) 551-559
6. Dasgupta M.K. Exit-site and catheter related infections in peritoneal dialysis: problems and progress. Nephrology 5 (2000) 17-25
7. Read R.R., Eberwein P., Dasgupta M.K., Grant S.K., Lam K., Nickel J.C., et al. Peritonitis in peritoneal dialysis: bacterial colonization by biofilm spread along the catheter surface. Kidney Int 35 (1989) 614-621
8. Bayston R., Andrews M., Rigg K., and Shelton A. Recurrent infection and catheter loss in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 19 (1999) 550-555
9. von Graevenitz A., and Amsterdam D. Microbiological aspects of peritonitis associated with continuous ambulatory peritoneal dialysis. Clin Microbiol Rev 5 1 (1992) 36-48
10. Kluytmans J.A.J.W., and Wertheim H.F.L. Nasal carriage of Staphylococcus aureus and prevention of nosocomial infections. Infection 33 1 (2005) 3-8
11. Cookson B.D. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 41 (1998) 11-18
12. Kim C.Y., Kumar A., Sampath L.A., Sokol K., and Modak S.M. Evaluation of an antimicrobial-impregnated continuous ambulatory peritoneal dialysis catheter for infection control in rats. Am J Kidney Dis 39 1 (2002) 165-173
13. Dasgupta M.K. Silver-coated catheters in peritoneal dialysis. Perit Dial Int 17 Suppl. 2 (1997) S142-S145
14. Trooskin S., Donetz A., Baxter J., Harvey R., and Greco R. Infection-resistant continuous peritoneal dialysis catheters. Nephron 46 (1987) 263-267
15. Bayston R., Grove N., Siegel J., Lawellin D., and Barsham S. Prevention of hydrocephalus shunt catheter colonisation in vitro by impregnation with antimicrobials. J Neurol Neurosurg Psychiatr 52 (1989) 605-609
16. Bayston R., and Lambert E. Duration of protective activity of cerebrospinal fluid shunt catheters impregnated with antimicrobial agents to prevent bacterial catheter-related infection. J Neurosurg 87 (1997) 247-251
17. Bayston R. Medical devices and methods of making medical devices. European Patent EP1804845 (W02006032904); 2007.
18. Bayston R., and Milner R.D.G. Antimicrobial activity of silicone rubber used in hydrocephalus shunts, after impregnation with antimicrobial substances. J Clin Pathol 134 (1981) 1057-1062
19. Eymann R., Chehab S., Strowitzki M., Steudel W.I., and Kiefer M. Clinical and economic consequences of antibiotic-impregnated cerebrospinal fluid shunt catheters. J Neurosurg Pediatr 1 (2008) 444-450
20. Govender S.T., Nathoo N., and van Dellen J.R. Evaluation of an antibiotic-impregnated shunt system for the treatment of hydrocephalus. J Neurosurg 99 (2003) 831-839
21. Zabramski J.M., Whiting D., Darouiche R.O., Horner T.G., Olson J., Robertson C., et al. Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. J Neurosurg 98 4 (2003) 725-730
22. Pattavilakom A., Xenos C., Bradfield O., and Danks R.S. Reduction in shunt infection using antibiotic impregnated CSF shunt catheters: an Australian prospective study. J Clin Neurosci 14 (2007) 526-531
23. Bayston R., Bhundia C., and Ashraf W. Hydromer-coated catheters to prevent shunt infection?. J Neurosurg 102 Suppl. 2 (2005) 207-212
24. Kaufmann A.F., Lye T., Redekop G., Brevner A., Hamilton M., Kozey M., et al. Infection rates in standard vs. hydrogel coated ventricular catheters. Can J Neurol Sci 31 4 (2004) 506-510
25. Bassetti S., Hu J., D'Agostino J.R., and Sherertz R.J. In vitro zones of inhibition of coated vascular catheters predict efficacy in preventing catheter infection with Staphylococcus aureus in vivo. Eur J Clin Microbiol Infect Dis 19 (2000) 612-617
26. Dhar N., and McKinney J.D. Microbial phenotypic heterogeneity and antibiotic tolerance. Curr Opin Microbiol 10 (2007) 30-38
27. Zhiao X., and Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 33 Suppl. 3 (2001) S147-S166
28. Kohnen W., Kolbenschlag C., Teske-Keiser S., and Jansen B. Development of a long-lasting ventricular catheter impregnated with a combination of antibiotics. Biomaterials 21 (2003) 4865-4869
29. Sharma S., Ramya T.N.C., Surolia A., and Surolia N. Triclosan as a systemic antibacterial agent in a mouse model of acute bacterial challenge. Antimicrob Agents Chemother 47 12 (2003) 3859-3866
30. ® suture (coated polyglactin 910 suture). Surg Infect 6 3 (2005) 313-321
31. Hernandez-Richter T.M., Wichman M.W., Schrödl W., Angele M.K., Heinritzi K., and Schildberg F.W. The acute phase response following implantation of triclosan-bonded vascular prostheses. Clin Exp Med 1 (2001) 35-41
32. Tulp M.T., Sunström G., Martron L.B., and Hutzinger O. Metabolism of chlorodiphenylethers and Irgasan DP300. Xenobiotica 9 (1979) 65-77
33. Müller G., and Kramer A. Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. J Antimicrob Chemother 61 (2008) 1281-1287